VNRX - VolitionRx stock slides on pricing $6M stock offering

• VolitionRx ( NYSE: VNRX ) shares dropped ~14% pre-market on Friday after the epigenetics company priced its $6M underwritten public offering of common stock.
• The offering consists of 3M shares issued at $2.00 each for a gross proceeds of $6M. Net proceeds will be used for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions.
• The underwriter has been granted a 30-day option to purchase up to an additional 450K shares of common stock at the public offering price.
• Offering is expected to close on or about August 2, 2022.

For further details see: